Camizestrant, a Next-Generation Oral SERD, Versus Fulvestrant in Post-Menopausal Women with Oestrogen Receptor-Positive, HER2-negative Advanced Breast Cancer (SERENA-2): a Multi-Dose, Open-Label, Randomised, Phase 2 Trial
LANCET ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined